- Home
- GSBC vs NTLA Comparison
GSBC vs NTLA Comparison
Compare GSBC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- NTLA
- Stock Information
- Founded
- GSBC 1923
- NTLA 2014
- Country
- GSBC United States
- NTLA United States
- Employees
- GSBC N/A
- NTLA N/A
- Industry
- GSBC Major Banks
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GSBC Finance
- NTLA Health Care
- Exchange
- GSBC Nasdaq
- NTLA Nasdaq
- Market Cap
- GSBC 665.7M
- NTLA 710.1M
- IPO Year
- GSBC N/A
- NTLA 2016
- Fundamental
- Price
- GSBC $55.94
- NTLA $6.87
- Analyst Decision
- GSBC Hold
- NTLA Buy
- Analyst Count
- GSBC 2
- NTLA 20
- Target Price
- GSBC $59.50
- NTLA $38.40
- AVG Volume (30 Days)
- GSBC 27.7K
- NTLA 5.0M
- Earning Date
- GSBC 07-15-2025
- NTLA 05-08-2025
- Dividend Yield
- GSBC 2.86%
- NTLA N/A
- EPS Growth
- GSBC 10.52
- NTLA N/A
- EPS
- GSBC 5.60
- NTLA N/A
- Revenue
- GSBC $219,572,000.00
- NTLA $45,569,000.00
- Revenue This Year
- GSBC N/A
- NTLA N/A
- Revenue Next Year
- GSBC $0.33
- NTLA N/A
- P/E Ratio
- GSBC $9.99
- NTLA N/A
- Revenue Growth
- GSBC N/A
- NTLA N/A
- 52 Week Low
- GSBC $47.58
- NTLA $5.90
- 52 Week High
- GSBC $68.02
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- GSBC 46.53
- NTLA 38.33
- Support Level
- GSBC $55.54
- NTLA $8.93
- Resistance Level
- GSBC $57.66
- NTLA $9.79
- Average True Range (ATR)
- GSBC 1.22
- NTLA 0.58
- MACD
- GSBC -0.28
- NTLA -0.15
- Stochastic Oscillator
- GSBC 18.20
- NTLA 1.35
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.